Getting pre-exposure prophylaxis to high-risk transgender women: lessons from Detroit, USA
| Autor: | Maureen D Connolly, Julisa Abad, Christine L. Heumann, Mary Roach, Jonathan Fritz, Julia E. Hood, Matthew R. Golden, Tony Eljallad, Dawn Lukomski |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Program evaluation Adult medicine.medical_specialty Michigan Cross-sectional study Anti-HIV Agents Population HIV Infections Transgender Persons Transgender women Health Services Accessibility 03 medical and health sciences Pre-exposure prophylaxis 0302 clinical medicine Hormone replacement therapy (female-to-male) Medicine Humans 030212 general & internal medicine education education.field_of_study Health Services Needs and Demand business.industry Public Health Environmental and Occupational Health Sexually Transmitted Diseases Viral 030112 virology Infectious Diseases Cross-Sectional Studies Family medicine Relative risk Chemoprophylaxis Female Pre-Exposure Prophylaxis business Program Evaluation |
| Zdroj: | Sexual health. 15(6) |
| ISSN: | 1448-5028 |
| Popis: | Background Pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention strategy, but it is unclear how best to deliver PrEP to key populations. Drawing upon a cross-sectional survey of transgender women (TW) in Detroit, USA, and experience of a PrEP clinic that serves this population, this manuscript describes the following: (1) the risk profile of Detroit TW; (2) the proportion of TW with at least one PrEP indication; and (3) perceptions of and experiences with PrEP among TW in Detroit. Methods: Between August 2017 and March 2018, 126 TW completed an online PrEP survey. Survey responses were summarised using descriptive statistics and multivariable relative risk regression. Results: Among participants who reported a negative or unknown HIV status (76% of all participants), 56% reported risk behaviour(s) consistent with PrEP indication guidelines, 17% reported currently taking PrEP and another 4% reported discontinued PrEP use. Among participants who met an indication for PrEP but were not currently taking PrEP, 64% indicated that they were not interested in taking PrEP. Approximately 60% of participants who were not currently taking PrEP reported that they would be more likely to take PrEP if it were provided at a clinic that also provided hormone replacement therapy. Conclusions: Although a substantial proportion of TW in our survey were on PrEP, interest in PrEP among high-risk TW who were not taking it was low. Specialised clinical infrastructure that is responsive to the specific needs of TW may be needed to expand PrEP to this oftentimes marginalised and high-risk population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|